


1

2 **Supplemental Figure 1: Characterization of *H. pylori* Lipopolysaccharide (LPS).**

3 LPS was purified from *H. pylori* strain J166. The LPS concentration was estimated based  
 4 on a lyophilized amebocyte lysate assay using *E. coli* LPS as a standard. *H. pylori* LPS  
 5 ( $0.5 \mu\text{g ml}^{-1}$ ) was incubated with SEAP reporter cell lines HEK-Blue™ Null2 (Null), HEK-  
 6 Blue™ hTLR4 (TLR4), HEK-Blue™ hTLR2 KO-TLR1/6 (KO 1/6), HEK-Blue™ hTLR2-  
 7 TLR1 (TLR2/1), and HEK-Blue™ hTLR2-TLR6 (TLR2/6) from InvivoGen. Relative  
 8 amounts of SEAP were measured after 16 hrs treatment. Results show the mean and  
 9 standard deviation from a single LPS preparation tested in triplicate and are  
 10 representative of three independent preparations of LPS.

11



12

13 **Supplemental Figure S2: Gastric inflammation in *H. pylori*-infected animals.**

14 Wild type C57Bl/6 mice were infected with two doses of *H. pylori* J166 (WT) or the  $\Delta Int$  mutant  
 15 strain VM391. Two weeks post-infection, gastric inflammation was scored on a 12-point  
 16 scale as described in Materials and Methods. The data represent results for individual  
 17 animals. Results were not significantly different between treatment groups (Mann-  
 18 Whitney U test).

19